膀胱癌循环肿瘤细胞NANOG基因的表达与临床特征相关性的初步研究

王力伟; 周晓洲; 陈志文; 杨劲

doi:10.16016/j.1000-5404.201711228

您当前的位置：

首页 >

文章列表页 >

膀胱癌循环肿瘤细胞NANOG基因的表达与临床特征相关性的初步研究

临床医学 | 更新时间：2026-01-09

- 膀胱癌循环肿瘤细胞NANOG基因的表达与临床特征相关性的初步研究
- Correlation of Nanog expression in circulating tumor cells with clinical characteristics of patients with bladder cancer
- 第三军医大学学报 2018年40卷第8期页码：711-716
- 作者机构：
  
  1.400038 重庆，陆军军医大学(第三军医大学):第一附属医院全军泌尿外科研究所
  2.400038 重庆，陆军军医大学(第三军医大学):基础医学院细胞生物教研室
- 作者简介：
  
  [陈志文，E-mail：zhiwen@tmmu.edu.cnCHEN Zhiwen, E-mail:zhiwen@tmmu.edu.cn
- 基金信息：
  
  第三军医大学临床医学研究重大专项基金(2012XLC02);国家自然科学基金面上项目(81372726)
- DOI：10.16016/j.1000-5404.201711228
  中图分类号： R181.32;R730.43;R737.14
- 收稿：2017-11-28，
  
  修回：2017-12-20，
  
  纸质出版：2018-04-30
- 稿件说明：
移动端阅览
王力伟, 周晓洲, 陈志文, 等. 膀胱癌循环肿瘤细胞NANOG基因的表达与临床特征相关性的初步研究[J]. 第三军医大学学报, 2018,40(8):711-716.

Liwei WANG, Xiaozhou ZHOU, Zhiwen CHEN, et al. Correlation of Nanog expression in circulating tumor cells with clinical characteristics of patients with bladder cancer[J]. Journal of Third Military Medical University, 2018, 40(8): 711-716.
王力伟, 周晓洲, 陈志文, 等. 膀胱癌循环肿瘤细胞NANOG基因的表达与临床特征相关性的初步研究[J]. 第三军医大学学报, 2018,40(8):711-716. DOI： 10.16016/j.1000-5404.201711228.

Liwei WANG, Xiaozhou ZHOU, Zhiwen CHEN, et al. Correlation of Nanog expression in circulating tumor cells with clinical characteristics of patients with bladder cancer[J]. Journal of Third Military Medical University, 2018, 40(8): 711-716. DOI： 10.16016/j.1000-5404.201711228.

摘要

目的

探讨膀胱癌患者外周血循环肿瘤细胞(circulating tumor cells，CTCs)及其中Nanog基因的阳性表达率与临床特征的相关性。

方法

选取2015年12月至2016年8月陆军军医大学第一附属医院全军泌尿外科研究所收治的膀胱尿路上皮癌患者59例，采用广州益善生物技术股份有限公司开发的Canpatrol

技术检测患者外周血中的CTCs分布情况及CTCs中Nanog基因的表达水平，分析上述检测结果与患者性别、年龄、肿瘤分级、浸润程度、淋巴结活检以及转移情况之间的相关性。

结果

肌层浸润性膀胱癌患者外周血中CTCs阳性率高于非肌层浸润性膀胱癌患者(33/36，91.7%

14/23，60.9%，

=0.007)；淋巴结活检阳性膀胱癌患者CTCs阳性率高于淋巴结活检阴性患者(19/20，95.0%

28/39，71.8%，

=0.044)；混合型CTCs中Nanog基因的阳性率高于上皮型(22/56，39.3%

96/176，54.5%，

=0.047)。

结论

CTCs可作为判断膀胱癌恶性程度和侵袭能力的辅助指标，CTCs中的Nanog基因有望成为评估膀胱癌转移和预后的生物标志。

Abstract

Objective

To investigate the correlation between Nanog expression in circulating tumor cells (CTCs) and the clinical features of patients with bladder cancer.

Methods

CTCs were isolated from 59 patients with bladder urothelial carcinoma and classified into epithelial

mesenchymal and bi-phenoty

pic CTCs. Nanog expression in the CTCs was detected using Canpatrol

technique. The positivity of CTCs and Nanog positivity in the CTCs were analyzed in these patients in relation with the patients' clinical features.

Results

The positivity rate of CTCs was significantly higher in patients with muscle invasive bladder cancer (MIBC) than in those with non-muscle invasive bladder cancer (NMIBC) [41/44 (93.2%)

6/15 (40.0%)

=0.007

]

and was also significantly higher in the patients with positive biopsy findings of the lymph nodes than in those with negative findings [19/20 (95.0%)

28/39 (71.8%)

=0.044

]

. Bi-phenotypic CTCs were found to have a higher rate of Nanog positivity than epithelial CTCs [22/56 (39.3%)

96/176 (54.5%)

=0.047

]

Conclusion

CTCs positivity can assist in the evaluation of malignancy and invasiveness of bladder cancer

and Nanog expression in the CTCs has the potential to serve as a biomarker for evaluating metastasis and prognosis of bladder cancer.

关键词

Keywords

references

PARKINSON D R, DRACOPOLI N, PETTY B G, et al . Considerations in the development of circulating tumor cell technology for clinical use[J ] . J Transl Med, 2012, 10: 138-157. DOI: 10.1186/1479-5876-10-138.

CARVALHO F L, SIMONS B W, ANTONARAKIS E S, et al . Tumorigenic potential of circulating pros tate tumor cells[J ] . Oncotarget, 2013, 4(3): 413-421. DOI: 10.18632/oncotarget.895.

NGUYEN L V, VANNER R, DIRKS P, et al . EAVES CJ(2012) Cancer stem cells: an evolving concept[J ] . Nat Rev Cancer, 2012, 12(2): 133-143. DOI: 10.1038/nrc3184.

MITSUI K, TOKUZAWA Y, ITOH H, et al . The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells[J ] . CELL, 2003, 113(5): 631-642. DOI: 10.1016/S0092-8674(03)00393-3.

WU S, LIU S, LIU Z, et al . Classification of circulating tumor cells by epithelial-mesenchymal transition markers[J ] . PLoS One, 2015, 10(4): e0123976. DOI: 10.1371/journal.pone.0123976.

GAWLIK-RZEMIENIEWSKA N, BEDNAREK I. The role of Nanog transcriptional factor in the development of malignant phenotype of cancer cells[J]. Cancer Biol Ther, 2016, 17(1): 1-10. DOI: 10.1080/15384047.2015.1121348.

FRIEDLANDER T W, PREMASEKHARAN G, PARIS P L. Looking back, to the future of circulating tumor cells[J]. Pharmacol Ther, 2014, 142(3): 271-280. DOI: /10.1016/j.pharmthera.2013.12.011.

ACETO N, BARDIA A, MIYAMOTO D T, et al . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis[J ] . Cell, 2014, 158(5): 1110-1122. DOI: 10.1016/j.cell.2014.07.013.

KÖNIGSBERG R, OBERMAYR E, BISES G, et al . Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients[J ] . Acta Oncol, 2011, 50(5): 700-710. DOI: 10.3109/0284186X.2010.549151.

WU S, LIU Z, LIU S, et al .Enrichment and enumeration of circulating tumor cells by efficient depletion of leukocyte fractions[J ] . Clin Chem Lab Med, 2013, 9: 1-9. DOI: 10.1515/cclm-2013-0558.

AIELLO N M, BRABLETZ T, KANG Y, et al . Upholding a role for EMT in pancreatic cancer metastasis[J ] . Nature, 2017, 547(7661): E7-E8. DOI: 10.1038/nature22963.

TURKER I, UYETURK U, SONMEZ O U, et al . Detection of circulating tumor cells in breast cancer patients: prognostic predictive role[J ] . Asian Pac J Cancer Prev, 2013, 14(3): 1601-1607. DOI: 10.7314/APJCP.2013.14.3.1601.

BORK U, RAHBARI N N, SCHOLCH S, et al .Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study[J ] . Br J Cancer, 2015, 112(8): 1306-1313. DOI: 10.1038/bjc.2015.88.

THALGOTT M, RACK B, HORN T, et al . Detection of circulating tumor cells in locally advanced high-risk prostate cancer during neoadjuvant chemotherapy and radical prostatectomy[J ] . Anticancer Res, 2015, 35(10): 5679-5685.

CHOU R, GORE J L, BUCKLEY D, et al . Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis[J ] . Ann Intern Med, 2015, 163(12): 922-931. DOI: 10.7326/m15-0997.DOI: 10.7326/M15-0997.

MICALIZZI D S, MAHESWARAN S, HABER D A. A conduit to metastasis: circulating tumor cell biology[J]. Genes Dev, 2017, 31(18): 1827-1840. DOI: 10.1101/gad.305805.117.

BEDNARZ-KNOLL N, ALIX-PANABI6RES C, PANTEL K. Plasticity of disseminating cancer cells in patients with epithelial malignancies [J]. Cancer Metastasis Rev, 2012, 31(3-4): 673-687. DOI10.1007/s10555-012-9370-z.

RINK M1, SOAV E A, ENGEL O, et al . Tumor cells in the peripheral blood of patients with urothelial carcinoma of the bladder: detection and impact of circulating[J ] . Urologe A, 2014, 53(4): 501-508. DOI: 10.1007/s00120-014-3443-2.

KREGEL S, SZMULEWITZ R Z, VANDER GRIEND D J. The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells [J]. Prostate, 2014, 74(15): 1530-1543. DOI: 10.1002/pros.22870.

LIU C W, LI C H, PENG Y J, et al . Snail regulates Nanog status during the epithelial-mesenchymal transition via the Smad1/Akt/GSK3β signaling pathway in non-small-cell lung cancer[J ] . Oncotarget, 2014, 5(11): 3880-3894. DOI: 10.18632/oncotarget.2006.

王志, 张艺, 黄亚琴, 等.干性基因Nanog在膀胱癌组织中的表达及其对膀胱癌细胞增殖与耐药的作用[J].第三军医大学学报, 2014, 36(7): 655-658. DOI: 10.16016/j.1000-5404.2014.07.023.

WANG Z, ZHANG Y, HUANG Y Q, et al . Expression of Nanog in bladder cancer and its role in proliferation and drug resistance of bladder cancer cells[J ] . J Third Mil Med Univ, 2014, 36(7): 655-658.DOI: 10.16016/j.1000-5404.2014.07.023

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

LRRC59促进膀胱尿路上皮癌细胞增殖、侵袭及凋亡抑制

干性基因Nanog在膀胱癌组织中的表达及其对膀胱癌细胞增殖与耐药的作用

PLXDC2调控丝状伪足形成促进胃癌侵袭转移的机制研究

巨噬细胞分泌TNF-α调控CLDN10通路促进膀胱癌细胞上皮-间质转化

ACSS2介导的上皮间质转化在乙醇促结直肠癌细胞迁移中的作用及机制